Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 29159748.
- Also identified by DOI 10.1245/s10434-017-6254-z and PMC identifier 5790421.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Molecular genomic testing provides clinicians with both prognostic and (sometimes) predictive information that can help individualize treatment and decrease the risk of over- or under-treatment. We review the genomic tests that are currently available for clinical use in management of breast cancer, discuss ongoing research related to validating and expanding their utility in different patient populations, and explain why it is important for surgeons to know how to incorporate these tools into their clinical practice in order to individualize patient treatment, reduce unnecessary morbidity, and, accordingly, improve outcomes.
Medical subject headings
- Biomarkers, Tumor
- Breast Neoplasms
- Decision Making
- Genetic Testing
- Patient Selection
- Surgeons
- Transcriptome